Insulet Corporation (PODD) fair value: what the stock is really worth
We calculate from audited financials what Insulet Corporation is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Insulet Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.
How to read this chart
60‑month range $127.77 – $352.82 · fair‑value band $74.35 – $218.74 · the $140.60 price screens below the $154.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Show more
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Stock analysis
Insulet Corporation (PODD) currently trades at $140.60, while our model-based Fair Value estimate is $154.66, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $165.74 per share, and 10 of the 26 models we run sit above the $140.60 price.
Bear case: the Economic Profit group reads lowest at $33.54, and 16 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $74.35 (bear) to $218.74 (bull), the price of $140.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Insulet Corporation reported revenue of $2.7B in FY2025 versus $1.1B in FY2021, a compound +25.3%/yr. Reported net income was $247M in FY2025, compounding +95.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap $11.0B · P/E ratio 33.5 · P/S ratio 3.05 · EPS (TTM) $4.20 · Dividend yield 0.1% · Net margin 9.1% · Return on equity 23.0% · Return on assets (EBIT) 8.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 60% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at 10%, PODD screens cheaper than that median.
Fair Value models
Bear $74.35Fair Value $154.66Bull $218.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($3.09 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+30.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.5%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+89.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+89.7%
Dividend (yield on the price)0.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 18%
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.7%
Yearly sales growth analysts expect, extended to five years.
News mood ⓘNews mood, the average tone of recent news (90 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 355 stocks
Beats the industry median on 7/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−47% · Below median
Profitability
Return on equity (TTM)23% · Top 25%
Return on assets10% · Top 25%
Net margin (TTM)10% · Above median
Operating margin (TTM)16% · Top 25%
Growth and dividend
Revenue growth34% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Insulet Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PODD
Frequently asked questions
Is Insulet Corporation (PODD) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of $154.66 versus a price of $140.60, about +10% upside (undervalued).
What is the fair value of PODD?
Our model-based fair value for Insulet Corporation is $154.66 (as of Sep 18, 2026), built from audited fundamentals. The current price: $140.60.
What is the quality score of PODD?
Insulet Corporation has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Insulet Corporation (PODD)?
Our model-based price target is the fair value of $154.66 (as of Sep 18, 2026) from 26 valuation models. Cautious scenario $74.35, optimistic scenario $218.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Insulet Corporation stock forecast for 2026?
Our models put fair value at $154.66, about +10% upside versus a price of $140.60 (undervalued). Cautious scenario $74.35, optimistic scenario $218.74. The calculation is refreshed regularly with new filings.
What is the revenue of Insulet Corporation (PODD)?
Insulet Corporation reported trailing-twelve-month revenue of about $2.9B (latest available figure, as of Sep 18, 2026).
Does Insulet Corporation pay a dividend?
Insulet Corporation currently shows a dividend yield of about 0.11% relative to its recent price (as of Sep 18, 2026).
What growth is priced into Insulet Corporation (PODD)?
For today's price to be fair in a discounted-cash-flow model, Insulet Corporation would have to grow free cash flow by +14.8 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.5 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of PODD use?
Our models discount Insulet Corporation at 9.5 %: a base by market capitalisation (large), damped by beta 1.11, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Insulet Corporation that is +14.8 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Insulet Corporation (PODD) delivered so far?
Over the past 5 years revenue at Insulet Corporation grew +24.5 % a year. The price currently implies +14.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Insulet Corporation (PODD) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Insulet Corporation (+14.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Insulet Corporation (PODD)?
The free-cash-flow yield on the price is 3.74 %: that much free cash flow Insulet Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Insulet Corporation (PODD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Insulet Corporation it is $154.66 per share (as of Sep 18, 2026), against a price of $140.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Insulet Corporation stock overvalued or undervalued in 2026?
As of Sep 18, 2026, PODD trades below its calculated fair value: price $140.60, fair value $154.66, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PODD?
No. The price is what the market pays today ($140.60); the fair value is what the company's own numbers justify ($154.66). For Insulet Corporation the two are $14.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Insulet Corporation worth?
The market values Insulet Corporation at about $11.0B (market capitalisation, as of Sep 18, 2026). Per share that is $140.60; our models calculate a fair value of $154.66 per share.
What do the bullish and bearish scenarios say about PODD?
Our models span a range for Insulet Corporation: cautious scenario $74.35, base $154.66, optimistic $218.74 per share (as of Sep 18, 2026, price $140.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PODD?
Insulet Corporation trades at a price-to-earnings ratio of 33.5 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $154.66 is built from several models across several years. Other multiples: PEG 1.4, P/B 7.3, P/S 3.8, EV/EBITDA 18.7.
What is the PEG ratio of PODD?
The PEG ratio of Insulet Corporation is 1.43 (P/E divided by earnings growth, as of Sep 18, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Insulet Corporation (PODD)?
Balance-sheet figures for Insulet Corporation (as of Sep 18, 2026): return on equity 23.0%, debt of 0.61 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is PODD from its 52-week high?
Insulet Corporation trades at $140.60, about 60% below its 52-week high of $354.88 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $154.66 is for.
Which stocks are comparable to Insulet Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Insulet Corporation stock attractive at the current price?
The data as of Sep 18, 2026: price $140.60, calculated fair value $154.66 (+10%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PODD calculated?
We run Insulet Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $154.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Insulet Corporation currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Insulet Corporation (PODD)?
The closing price on Sep 18, 2026 was $140.60. Our model-based fair value is $154.66, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Insulet Corporation right now?
The model range is unusually wide ($74.35 to $218.74). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Insulet Corporation
How large is the market capitalisation of Insulet Corporation (PODD)?
The market capitalisation of Insulet Corporation is $11.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Insulet Corporation (PODD)?
The price-to-sales ratio of Insulet Corporation is 3.05 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Insulet Corporation (PODD)?
Earnings per share at Insulet Corporation are $4.20 (price ÷ EPS = P/E 33.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Insulet Corporation (PODD)?
The dividend yield of Insulet Corporation is 0.1% (payout 3.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Insulet Corporation (PODD)?
The net margin of Insulet Corporation is 9.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Insulet Corporation (PODD)?
The return on equity (ROE) of Insulet Corporation is 23.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Insulet Corporation (PODD)?
On an EBIT basis the return on assets of Insulet Corporation is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Insulet Corporation (PODD)?
The operating margin of Insulet Corporation is 16.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Insulet Corporation (PODD)?
Revenue at Insulet Corporation is growing +33.9% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Insulet Corporation (PODD)?
Earnings per share at Insulet Corporation are growing +159% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Insulet Corporation (PODD) carry?
The net debt of Insulet Corporation is $335M (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Insulet Corporation in the live analysis
One click puts Insulet Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 18, 2026